2020
-
November 25, 2020 Pharmaceuticals PDF236 KB
-
November 13, 2020 Corporate PDF644 KB
-
November 05, 2020 Management & Finance
Outline of Consolidated Financial Results for the Second Quarter Ended September 30, 2020
-
August 20, 2020 Pharmaceuticals PDF255 KB
VILTEPSO (viltolarsen) injection Now Commercially Available in the U.S.
-
August 13, 2020 Pharmaceuticals PDF266 KB
VILTEPSO (viltolarsen) Now Approved in the U.S. for the Treatment of Duchenne Muscular Dystrophy
-
August 11, 2020 Management & Finance
Outline of Consolidated Financial Results for the First Quarter Ended June 30, 2020
-
July 01, 2020 Management & Finance PDF153 KB
-
June 08, 2020 R & D PDF266 KB
(Media)EC Grants Orphan Drug Designation to viltolarsen (NS-065/NCNP-01)
-
May 29, 2020 Pharmaceuticals PDF353 KB
-
May 20, 2020 Pharmaceuticals PDF242 KB
-
May 13, 2020 Management & Finance
Outline of Consolidated Financial Results for the Year Ended March 31, 2020
-
May 12, 2020 R & D PDF260 KB
-
April 28, 2020 Pharmaceuticals PDF216 KB
(Media)Notification of MA Transfer Completion of Tadalafil Products
-
March 25, 2020 Pharmaceuticals PDF277 KB
-
February 07, 2020 Pharmaceuticals PDF238 KB
(Media)NDA Accepted for Filing by the FDA for Antisense Oligonucleotide Viltolarsen (NS-065/NCNP-01)
-
February 07, 2020 Corporate PDF303 KB
-
February 05, 2020 Management & Finance
Outline of Consolidated Financial Results for the Third Quarter Ended December 31, 2019